Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Acromegaly | Case report

Caloric restriction as a possible pitfall for persistent acromegaly follow-up – case report

Authors: Ana Filipa Martins, Mónica Santos, Francisco Rosário

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Acromegaly diagnosis is established when plasma levels of IGF-1 are increased and the Oral Glucose Tolerance Test (OGTT) with 75gr of glucose can’t suppress Growth Hormone (GH) levels. These two parameters are also useful during follow-up, after surgical/radiologic therapy and/or during medical therapy.

Case presentation

A 29-year-old woman was diagnosed with acromegaly after a severe headache. Previous amenorrhea and facial and acral changes were noticed. A pituitary macroadenoma was found, biochemical evaluation was in agreement with the suspected acromegaly and a transsphenoidal adenectomy was performed. As the disease recurred, a surgical reintervention and radiosurgery (Gamma Knife, 22 Gy) were necessary. No normalization of IGF-1 was achieved during three years after radiosurgery. Surprisingly, then, and although clinical features seemed getting worse, IGF-1 levels became consistently controlled to 0.3–0.8 times the upper limit of the reference range. Questioned, the patient referred that she was following an intermittent fasting dietary plan. However, based on the dietary questionnaire, she was found to be under severe caloric restriction. First OGTT (under caloric restriction) showed absence of GH suppression and an IGF-1 value of 234 ng/dL (Reference Range 76–286 ng/mL). A second OGTT, one month after an eucaloric diet was instituted, showed an increased IGF-1 of 294 ng/dL, maintaining an unsuppressed, yet less elevated, GH.

Conclusions

GHRH/GH/IGF-1 axis controls somatic growth. Regulation is complex, and nutrition status and feeding pattern have a recognized role. Like systemic inflammation or chronic liver disease, fasting and malnutrition decrease the expression of hepatic GH receptors, with consequent reduction of IGF-1 levels, through resistance to GH. This clinical report shows that caloric restriction may represent a pitfall in acromegaly follow-up.
Literature
5.
go back to reference Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, Renoult PP, Houchard A, Elaraki F, Chanson P. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine. 2019;63(1):120–9. https://doi.org/10.1007/s12020-018-1764-4. Epub 2018 Sep 29. Erratum in: Endocrine. 2018 Oct 31;PMID: 30269264; PMCID: PMC6329724.CrossRefPubMed Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B, Renoult PP, Houchard A, Elaraki F, Chanson P. Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study. Endocrine. 2019;63(1):120–9. https://​doi.​org/​10.​1007/​s12020-018-1764-4. Epub 2018 Sep 29. Erratum in: Endocrine. 2018 Oct 31;PMID: 30269264; PMCID: PMC6329724.CrossRefPubMed
7.
go back to reference Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson- Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176:645–55. https://doi.org/10.1530/EJE-16-1064.CrossRefPubMed Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson- Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176:645–55. https://​doi.​org/​10.​1530/​EJE-16-1064.CrossRefPubMed
9.
go back to reference Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe- Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, Cuevas-Ramos D, Melgar V, Talavera J, Rivera-Hernandez AJ, et al. The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101:3997–4004. https://doi.org/10.1210/jc.2016-1937.CrossRefPubMed Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe- Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, Cuevas-Ramos D, Melgar V, Talavera J, Rivera-Hernandez AJ, et al. The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101:3997–4004. https://​doi.​org/​10.​1210/​jc.​2016-1937.CrossRefPubMed
15.
17.
go back to reference Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69–73.CrossRefPubMed Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69–73.CrossRefPubMed
18.
go back to reference Melmed S, Auchus R, Goldfine A, et al. Williams textbook of Endocrinology, 14th edition; Chapter 8: Pituitary Physiology and Diagnostic Evaluation. Elsevier; 2020. Melmed S, Auchus R, Goldfine A, et al. Williams textbook of Endocrinology, 14th edition; Chapter 8: Pituitary Physiology and Diagnostic Evaluation. Elsevier; 2020.
20.
23.
go back to reference Coopmans E.C, Berk K.A.C, El-Sayed N, Neggers S.J.C.M.M, van der Lely A.J. Eucaloric very-low-carbohydrate ketogenic diet in acromegaly treatment. N Engl J Med. 2020;382:2161–2.CrossRefPubMed Coopmans E.C, Berk K.A.C, El-Sayed N, Neggers S.J.C.M.M, van der Lely A.J. Eucaloric very-low-carbohydrate ketogenic diet in acromegaly treatment. N Engl J Med. 2020;382:2161–2.CrossRefPubMed
Metadata
Title
Caloric restriction as a possible pitfall for persistent acromegaly follow-up – case report
Authors
Ana Filipa Martins
Mónica Santos
Francisco Rosário
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01319-0

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.